Head-To-Head Survey: Bausch + Lomb (NYSE:BLCO) and Charles River Laboratories International (NYSE:CRL)

Bausch + Lomb (NYSE:BLCO) and Charles River Laboratories International (NYSE:CRL) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, earnings and valuation.

Earnings & Valuation

This table compares Bausch + Lomb and Charles River Laboratories International”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10 billion	1.10	-$360.00 million	($0.62)	-25.39
Charles River Laboratories International	$4.02 billion	1.97	-$144.34 million	($3.76)	-43.77

Charles River Laboratories International has lower revenue, but higher earnings than Bausch + Lomb. Charles River Laboratories International is trading at a lower price-to-earnings ratio than Bausch + Lomb, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Bausch + Lomb has a beta of 0.59, indicating that its share price is 41% less volatile than the S&P 500. Comparatively, Charles River Laboratories International has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500.

Profitability

This table compares Bausch + Lomb and Charles River Laboratories International’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-4.21%	3.60%	1.69%
Charles River Laboratories International	-4.59%	15.36%	6.61%

Insider and Institutional Ownership

11.1% of Bausch + Lomb shares are held by institutional investors. Comparatively, 98.9% of Charles River Laboratories International shares are held by institutional investors. 1.5% of Bausch + Lomb shares are held by company insiders. Comparatively, 1.3% of Charles River Laboratories International shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Bausch + Lomb and Charles River Laboratories International, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1	9	4	0	2.21
Charles River Laboratories International	1	4	10	0	2.60

Bausch + Lomb currently has a consensus price target of $18.08, indicating a potential upside of 14.90%. Charles River Laboratories International has a consensus price target of $207.69, indicating a potential upside of 26.21%. Given Charles River Laboratories International’s stronger consensus rating and higher possible upside, analysts plainly believe Charles River Laboratories International is more favorable than Bausch + Lomb.

Summary

Charles River Laboratories International beats Bausch + Lomb on 9 of the 14 factors compared between the two stocks.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation is a subsidiary of Bausch Health Companies Inc.

About Charles River Laboratories International

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.